HS Is Systemic, Not Isolated — Why the Skin Is Not the Disease

The Classification Problem

Hidradenitis suppurativa is classified, in most medical and patient-facing literature, as a chronic inflammatory skin condition. This classification is not wrong in the narrow sense — HS does involve chronic inflammation, and that inflammation does express itself through the skin. But as a description of what HS actually is and where it actually operates, it is significantly incomplete. And the incompleteness has consequences that affect every patient who seeks treatment for it.

When a condition is classified as dermatological, treatment follows that classification. Dermatologists evaluate it; dermatological interventions are applied; success is measured against skin-level outcomes. The internal processes that are driving the skin presentation are not the primary target of evaluation or intervention — because the framework that governs the evaluation does not require them to be. The result is a treatment architecture that is well-matched to the expression of the disease but systematically mismatched to its origin.

This is not a failure of the clinicians involved. It is a consequence of the classification. If HS is a skin condition, treating the skin is the logical and appropriate response. The problem is that HS is not, at its origin, a skin condition. The skin is where it becomes visible. The internal systems that generate the visibility are where it actually lives.

The Systems Actually Involved

A full account of the systems involved in HS reveals a picture that is substantially more complex than a localised skin condition.

The gastrointestinal system is the origin point of the sustained inflammatory signal that drives HS in a large proportion of patients. A compromised intestinal barrier allows inflammatory compounds to enter systemic circulation, where they sustain the immune activation that HS requires to express itself. The gut microbiome regulates immune function, hormonal clearance, and the integrity of the intestinal barrier itself — and when it is dysregulated, these regulatory functions fail simultaneously. This is not a peripheral connection. For many patients, it is the central mechanism driving their disease.

The endocrine system — specifically the adrenal, gonadal, and pancreatic components of hormonal regulation — contributes through androgen excess, insulin resistance, and the complex interactions between these two factors. Androgens regulate follicular keratinisation and sebum production, directly creating the follicular susceptibility that HS exploits. Insulin resistance amplifies androgen availability and worsens systemic inflammation simultaneously. In women with PCOS, these two drivers are particularly tightly linked — which is why PCOS-associated HS tends to behave differently, and more persistently, than HS without this hormonal substrate.

The immune system is not merely a bystander that happens to produce the inflammation visible in HS lesions. It is a dysregulated participant — one whose regulatory functions have been impaired by years of sustained activation, and whose response to follicular events in HS-affected tissue is characteristically disproportionate. The immune system does not create HS, but it determines the severity, depth, and tissue-destructive character of its expression.

The lymphatic system contributes through its role in clearance. The anatomical locations where HS predominantly occurs — underarms, groin, beneath the breast — are areas of high lymphatic density. In the context of sustained systemic inflammation, lymphatic function in these areas tends toward congestion, reducing the efficiency with which inflammatory debris and metabolic waste products are cleared from the local tissue environment. This creates a persistently primed local state that lowers the threshold for the next lesion.

The metabolic system — glucose regulation, lipid metabolism, adipose tissue function — interacts with every other driver. Visceral adiposity produces its own inflammatory mediators. Insulin resistance impairs multiple regulatory functions simultaneously. Metabolic dysfunction compounds hormonal imbalance and amplifies the systemic inflammatory burden. In a significant proportion of HS patients, metabolic correction is not a supporting element of treatment — it is a primary target.

Why These Systems Interact — The Compounding Architecture

The systems involved in HS do not operate in parallel — they interact, and in chronic HS, they typically compound each other. This compounding architecture is one of the reasons HS is harder to correct than conditions driven by a single system disruption.

Gut dysfunction worsens immune regulation by reducing the gut's capacity to generate the regulatory immune signals that limit inflammation. Impaired immune regulation worsens hormonal balance, because sustained immune activation disrupts the hypothalamic-pituitary-adrenal axis that coordinates hormonal output. Hormonal imbalance — specifically androgen excess and insulin resistance — worsens gut function through effects on gut motility, microbiome composition, and intestinal barrier integrity. Each system's dysfunction feeds the others. The longer the disease has been established, the more deeply these interactions have become entrenched.

This is why HS in a patient who has had the condition for fifteen years does not respond to correction in the same way as HS in a patient who has had it for two. The compounding has been operating longer. The systems involved have adapted more completely to the disease state. Correction is possible — but it requires engaging with the full systemic picture, not just the most visible disruption.

The Consequence of Treating a Systemic Disease as a Local One

The practical consequence of treating HS as a local skin condition is the cycle that defines the experience of most long-term patients: treatment that produces temporary improvement — because it reduces the current expression of the disease — followed by relapse when that treatment is withdrawn or becomes ineffective — because it never altered the internal state generating the expression.

Antibiotics are the most common example. They reduce the bacterial component of active HS lesions, producing genuine short-term improvement. But they do not address gut dysfunction, hormonal imbalance, immune dysregulation, or metabolic disruption. When the course ends, the internal state that was generating the lesions is intact. New lesions form — often more quickly than before, because the antibiotic course has itself worsened the gut dysbiosis that is one of the disease's primary drivers. The cycle continues, each iteration leaving the internal architecture of the disease slightly more established than before.

Surgical intervention produces a similar pattern at a different level. It removes the structural consequences of HS — the sinus tracts, the fibrosed tissue, the established lesion architecture — without altering the internal state that produced them. The tissue is cleared; the system generating new tissue involvement is not. New lesions develop in adjacent areas with a frequency and pattern that reflects an internal environment that has not changed.

What Systemic Treatment Actually Requires

Treating HS as the systemic condition it is requires a fundamentally different starting point: evaluation of internal systems, not just skin presentation. Before a treatment approach can be personalised — and personalisation is essential, because the specific combination of internal drivers differs between patients — the internal picture must be understood. Which systems are primarily disrupted? How are they interacting? What has the disease history done to the compounding architecture? What is the current stage, and how does that affect what correction can realistically achieve?

These questions cannot be answered by examining the skin. They require a broader evaluation — one that takes the disease seriously as a systemic condition and directs investigation and intervention accordingly. The skin presentation provides useful information about severity, location, and stage. But it does not reveal the internal architecture that produced it. That architecture is where treatment must be directed — and that is precisely what skin-directed treatment, operating within a classification that does not require it to look deeper, consistently fails to reach.

Why This Matters for Patients

For patients who have been through multiple rounds of skin-directed treatment without sustained improvement, the systemic framing of HS is not just intellectually useful. It is practically clarifying. It explains why previous treatments produced temporary results. It explains why the condition keeps returning. And it points clearly toward what a different kind of treatment must address — not because the previous clinicians were incompetent, but because they were operating within a framework that directed their attention toward the wrong level of the disease.

Understanding HS as systemic also changes what questions patients can usefully ask about their own condition. Not "how do I stop this lesion?" but "what internal state is generating this lesion, and what would it take to change that state?" Not "how long until this clears?" but "what is the trajectory of my internal correction, and what markers tell me it is working?" These are questions that a systemic framing makes answerable. A skin-level framing does not.